查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
到 2030 年內分泌治療的市場預測：按治療領域、配銷通路、給藥途徑、最終用戶和地區進行的全球分析
市場調查報告書
商品編碼
1383312

到 2030 年內分泌治療的市場預測：按治療領域、配銷通路、給藥途徑、最終用戶和地區進行的全球分析

Endocrinology Drugs Market Forecasts to 2030 - Global Analysis By Therapy Area, Distribution Channel, Route of Administration, End User and By Geography.
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球內分泌治療市場規模為 62.5 億美元，預計預測期內年複合成長率為 14.3%，到 2030 年將達到 159.3 億美元。

內分泌藥物是一種旨在靶向和調節內分泌系統功能的藥物物質。這些藥物用於治療多種內分泌疾病和病症，包括糖尿病、甲狀腺疾病、腎上腺疾病和荷爾蒙失衡。這些藥物的給藥方式多種多樣，包括口服藥物、注射和局部治療，取決於特定病情和所涉及的荷爾蒙。

根據國際糖尿病基金會 (IDF) 2021 年的最新數據，到 2021 年，大約有 5.37 億成年人（20-79 歲）將患有糖尿病。

內分泌疾病盛行率增加

內分泌疾病盛行率的增加是內分泌治療市場的關鍵促進因素。久坐的生活方式和不良飲食習慣等生活方式的改變導致糖尿病和肥胖等疾病的增加，並且通常需要內分泌藥物來控制這兩種疾病。人們越來越擔心荷爾蒙失衡和相關疾病的增加是由於接觸內分泌干擾物等環境因素造成的。此外，這些綜合因素正在創造對內分泌治療的持續需求，導致製藥公司不斷發展和行銷創新治療方法，以滿足不斷成長的患者群體的需求。

研究開發費用

研究和開發（R＆D）成本是內分泌治療市場的主要抑制因素。開發新的內分泌治療方法需要大量的財務投資，通常需要多年的臨床試驗。高研發成本可能會給製藥公司帶來財務壓力，特別是如果一種有前景的藥物在後期臨床試驗中失敗的話。這些成本導致藥品價格上漲，並引起醫療保健支付者和政府的審查。嚴格的安全性和有效性測試的需要進一步增加了財務負擔。平衡創新需求與高昂的研發成本是一個困難因素，迫使製藥公司在競爭激烈的內分泌市場中仔細選擇和優先考慮潛在的候選藥物，這一點至關重要。

聯合治療的發展

聯合治療已成為內分泌領域的一個充滿希望的機會，為治療各種內分泌疾病提供了潛在的益處。透過結合不同的藥物和治療方法，聯合治療可以產生協同效應，提高治療效果和患者緩解率。它還可以解決抗藥性等問題，並降低與給藥大劑量單一藥物相關的副作用風險。此外，聯合治療可以同時針對特定的疾病機製或途徑，從而產生更全面和個體化的治療策略。這種方法在糖尿病、甲狀腺疾病和荷爾蒙失衡等疾病的治療中尤其重要。隨著對內分泌疾病認知的深入和新型治療藥物的開發，聯合治療的探索和發展已成為最佳化內分泌治療效果的重要機會。因此，預計市場擴張將出現良好的成長。

法規挑戰

法規挑戰對內分泌市場構成重大威脅。內分泌療法的開發、核准和商業化受到嚴格且不斷發展的法規的約束。 FDA 等法規機構制定了嚴格的標準來確保安全性和有效性，這可能會導致核准時間更長和合規成本更高。遵守這些標準需要大量的財力和人力資源，這可能會抑制研發投資。此外，法規要求的變化可能會影響市場形勢，我們必須不斷適應。因此，這些挑戰阻礙了市場的成長。

COVID-19 的影響

COVID-19 的爆發對內分泌治療市場產生了重大影響。醫療保健系統對病毒管理的關注導致了內分泌疾病診斷和治療的混亂。此外，供應鏈中斷和藥物短缺給維持內分泌治療的穩定供應帶來了挑戰。然而，大流行加速了遠端醫療的普及，為遠端監控和處方管理提供了新途徑。畢竟，內分泌治療市場在大流行期間面臨複雜的情況，包括延誤、藥物短缺和不斷變化的醫療服務模式。

預計糖尿病藥物領域在預測期內將是最大的

由於糖尿病患者數量的增加、糖尿病治療藥物開發的增加以及糖尿病治療研發投入的增加，預計糖尿病治療領域將佔據最大佔有率。全球糖尿病的高盛行率以及缺乏有前途且有效的糖尿病治療藥物也推動了這一領域的成長。此外，主要企業和政府機構增加對糖尿病藥物開發的投資預計將推動該領域的成長。因此，由於糖尿病患者數量的增加以及用於開發抗糖尿病藥物的研究資金的增加，預計糖尿病細分市場將顯著成長。

醫院藥房業務預計在預測期內年複合成長率最高

預計醫院藥局部門在預測期內將出現良好成長。內分泌藥物旨在解決荷爾蒙失衡和相關疾病。在這一領域，醫院藥局是重要的配送中心，確保患者以受控且及時的方式獲得正確的藥物。他們還在患者教育中發揮重要作用，幫助患者了解內分泌藥物的正確使用和潛在副作用。此外，醫院藥房與內分泌科醫生合作，確保治療計劃（通常涉及複雜的藥物治療）得到有效實施。因此，醫院藥局是內分泌治療市場的重要組成部分，有助於最佳化病患照護和內分泌疾病管理。

比最大的地區

由於人口高齡化加劇增加了內分泌疾病的風險，北美在預測期內獲得了最大的市場佔有率。美國和加拿大肥胖病例的增加導致許多內分泌疾病的發生率增加，包括糖尿病、胰島素抗性和甲狀腺問題。糖尿病是最常見的內分泌疾病，盛行率很高，對區域市場的收益貢獻很大。此外，美國糖尿病教育者美國和美國糖尿病協會等組織正在推動擴大該地區的病患教育。

複合年複合成長率最高的地區：

由於生長激素缺乏症盛行率上升以及該地區研發的預期成長，預計亞太地區在預測期內將實現盈利成長。該地區的內分泌治療市場可能會受益於與內分泌系統和糖尿病相關的癌症（包括末期腎病）盛行率的不斷上升。此外，社會對更年期性交困難和外陰陰道萎縮等罕見內分泌疾病的認知不斷提高，預計將在估計期間推動市場成長。此外，各種研究範式的實施，例如引入治療內分泌疾病的新藥和藥物組合，預計也將促進該地區的成長。

提供免費客製化：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球內分泌治療市場：依治療領域

  • 糖尿病藥物
  • 生長激素紊亂
  • 治療甲狀腺激素失調的藥物
  • 睾酮替代療法
  • 骨質疏鬆症
  • 腎上腺皮質功能不全
  • 性腺功能減退症
  • 其他治療領域

第6章 全球內分泌治療市場：依配銷通路

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 其他配銷通路

第7章 全球內分泌治療市場：依給藥途徑

  • 口服
  • 經皮的
  • 注射

第8章 全球內分泌治療市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 其他最終用戶

第9章 全球內分泌治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章公司簡介

  • Abbott Laboratories,
  • Eli Lilly And Company
  • F. Hoffmann La Roche Ltd.
  • Novartis International AG
  • Pfizer Inc.
  • Alacer Corporation
  • Novo Nordisk A/S
  • Facet Biotech Corporation
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Merck KGaA
  • AstraZeneca Plc
  • Lee Pharmaceuticals
  • MannKind
  • Acerus Pharmaceuticals Corp
  • Bayer AG
  • Endo International Plc
  • Beta Cell NV
  • Hanmi Pharm Co. Ltd
  • Ipsen Pharma
Product Code: SMRC24162

According to Stratistics MRC, the Global Endocrinology Drugs Market is accounted for $6.25 billion in 2023 and is expected to reach $15.93 billion by 2030 growing at a CAGR of 14.3% during the forecast period. Endocrinology drugs are pharmaceutical substances designed to target and regulate the functions of the endocrine system. These drugs are used to treat a wide range of endocrine disorders and conditions, such as diabetes, thyroid disorders, adrenal gland disorders, and hormonal imbalances. These drugs can be administered in various forms, including oral medications, injections, and topical treatments, depending on the specific condition and the hormone involved.

According to the International Diabetic Foundation (IDF) 2021 update, approximately 537 million adults (20-79 years) were living with diabetes in 2021.

Market Dynamics:

Driver:

Growing prevalence of endocrine disorders

The growing prevalence of endocrine disorders is a significant driver of the endocrinology drug market. Lifestyle changes, including sedentary behaviour and poor dietary habits, have led to an increase in conditions like diabetes and obesity, both of which often require endocrinology medications for management. The increasing prevalence of hormonal imbalances and associated diseases has raised concerns and been attributed to environmental factors, such as exposure to endocrine-disrupting substances. Furthermore, these combined factors create a sustained demand for endocrinology drugs, providing growth for pharmaceutical companies to develop and market innovative treatments that address the needs of an expanding patient population.

Restraint:

Research and development costs

Research and Development (R&D) costs are a significant restraint in the endocrinology drugs market. Developing new endocrinology medications demands substantial financial investments, often spanning many years and clinical trials. High R&D expenditures can lead to financial strain for pharmaceutical companies, especially if promising drugs fail in late-stage trials. These costs contribute to elevated drug prices, attracting scrutiny from healthcare payers and governments. The need for rigorous safety and efficacy testing further increases the financial burden. Balancing the imperative for innovation with the substantial R&D expenses is a challenging restraint, making it essential for pharmaceutical firms to carefully select and prioritize potential drug candidates in the highly competitive endocrinology market.

Opportunity:

Development of combination therapies

Combination therapies have emerged as a promising opportunity in the field of endocrinology, offering potential benefits for the treatment of various endocrine disorders. By combining different drugs or treatment approaches, combination therapies can provide synergistic effects, improving treatment outcomes and patient response rates. They can also help address issues such as drug resistance and reduce the risk of adverse effects associated with high doses of a single medication. Moreover, combination therapies offer the potential to target specific disease mechanisms or pathways simultaneously, leading to more comprehensive and personalised treatment strategies. This approach is especially relevant in the management of conditions like diabetes, thyroid disorders, and hormonal imbalances. With ongoing advancements in understanding endocrine disorders and the development of novel therapeutic agents, the exploration and development of combination therapies present a significant opportunity to optimise treatment outcomes in endocrinology. Thus, there is lucrative growth for market expansion.

Threat:

Regulatory challenges

Regulatory challenges present a substantial threat to the endocrinology market. The development, approval, and commercialization of endocrinology drugs are subject to stringent and evolving regulations. Regulatory agencies, such as the FDA, impose rigorous standards to ensure safety and efficacy, which can lead to protracted approval timelines and high compliance costs. Compliance with these standards demands substantial financial and human resources, potentially discouraging investment in research and development. Additionally, changes in regulatory requirements can impact the market landscape, necessitating constant adaptation. Thus, these challenges are hampering market growth.

COVID-19 Impact

The COVID-19 pandemic had a significant impact on the endocrinology drugs market. The healthcare system's focus on managing the virus led to disruptions in the diagnosis and treatment of endocrine disorders. Additionally, supply chain disruptions and drug shortages posed challenges in maintaining a steady supply of endocrinology drugs. However, the pandemic also accelerated telehealth adoption, offering new avenues for remote monitoring and prescription management. Ultimately, the endocrinology drugs market faced a complex landscape of delays, drug shortages, and evolving healthcare delivery models during the pandemic.

The Diabetes Drugs segment is expected to be the largest during the forecast period

The Diabetes Drugs segment is estimated to hold the largest share, owing to the increase in cases of diabetes, the rise in the development of diabetic drugs, and the increase in investment in the development of diabetic drug research. Also, the high prevalence of diabetes across the globe and the unavailability of promising and effective drug products for the treatment of diabetes spurs the growth of this segment. Furthermore, a rise in investments in the development of diabetic drugs by key players or government agencies is expected to fuel the growth of the segment. Hence, due to the rise in cases of diabetes and the increase in research funding for the development of diabetic drugs, the diabetes segment is expected to witness significant growth.

The Hospital Pharmacies segment is expected to have the highest CAGR during the forecast period

The Hospital Pharmacies segment is anticipated to have lucrative growth during the forecast period. Endocrinology drugs are designed to address hormonal imbalances and related conditions. In this segment, hospital pharmacies serve as key distribution points; ensuring patients receive the right medications in a controlled and timely manner. They also play a pivotal role in patient education, helping individuals understand the proper use and potential side effects of endocrinology drugs. Moreover, hospital pharmacies collaborate with endocrinologists to ensure tailored treatment plans, often involving complex medication regimens, are effectively implemented. Hence, hospital pharmacies are vital components of the endocrinology drugs market, facilitating optimal patient care and management of endocrine disorders.

Region with largest share:

North America commanded the largest market share during the extrapolated period due to the growing ageing population, which increases the risk of endocrine disorders. Increases in the incidence of a number of endocrine disorders, including diabetes, insulin resistance, and thyroid issues, can be attributed to the rise in obesity cases in the US and Canada. The most prevalent endocrine condition, diabetes, has a high prevalence and contributes significantly to regional market income. Moreover, the American Association of Diabetes Educators and the American Diabetes Association, among other groups, are driving the expansion of the patient education sector in the region.

Region with highest CAGR:

Asia- Pacific region is expected to witness profitable growth over the projection period, owing to a rise in the prevalence of growth hormone deficiency and the expected growth of research and development in the region. The market for endocrinology drugs in the area will benefit from an increase in the incidence of cancers related to the endocrine system and diabetes, including end-stage renal disease. Furthermore, throughout the duration of the estimated time frame, rising public awareness of infrequently occurring endocrine disorders-such as dyspareunia and vulvar and vaginal atrophy caused by menopause-is anticipated to fuel the market's growth. Various research paradigms carried out, such as the introduction of novel drugs and combination pharmaceuticals for the treatment of endocrine disorders, are also expected to boost the region's growth.

Key players in the market

Some of the key players in the Endocrinology Drugs Market include: Abbott Laboratories, Eli Lilly And Company, F. Hoffmann La Roche Ltd., Novartis International AG, Pfizer Inc., Alacer Corporation , Novo Nordisk A/S, Facet Biotech Corporation, Sanofi, Takeda Pharmaceutical Company Limited, Merck KGaA, AstraZeneca Plc, Lee Pharmaceuticals, MannKind, Acerus Pharmaceuticals Corp, Bayer AG, Endo International Plc, Beta Cell NV, Hanmi Pharm Co. Ltd and Ipsen Pharma.

Key Developments:

In March 2023, Eton Pharmaceuticals, a pharmaceutical company focused on developing and commercializing treatments for rare diseases, acquired a rare disease product candidate, ET-600, from Tulex Pharmaceuticals. ET-600 is an innovative product candidate under development for treating an endocrinology condition estimated to impact less than 5,000 pediatric patients in the United States.

In February 2023, Akums Drugs and Pharmaceutical Limited, a contract drug manufacturing company, received approval from the Drug Controller-General of India (DCGI) for their product Lobeglitazone, an anti-diabetic drug. The drug is a new formulation manufactured specifically for type 2 diabetic patients by helping them improve pancreatic beta-cell function.

Therapy Areas Covered:

  • Diabetes Drugs
  • Growth Hormone Disorders
  • Thyroid Hormone Disorder Drugs
  • Testosterone Replacement Therapy
  • Osteoporosis
  • Adrenal insufficiency
  • Hypogonadism
  • Other Therapy Areas

Distribution Channels Covered:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Other Distribution Channels

Route of Administrations Covered:

  • Oral
  • Transdermal
  • Injectable

End Users Covered:

  • Ambulatory Surgical Centers
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Endocrinology Drugs Market, By Therapy Area

  • 5.1 Introduction
  • 5.2 Diabetes Drugs
  • 5.3 Growth Hormone Disorders
  • 5.4 Thyroid Hormone Disorder Drugs
  • 5.5 Testosterone Replacement Therapy
  • 5.6 Osteoporosis
  • 5.7 Adrenal insufficiency
  • 5.8 Hypogonadism
  • 5.9 Other Therapy Areas

6 Global Endocrinology Drugs Market, By Distribution Channel

  • 6.1 Introduction
  • 6.2 Hospital Pharmacies
  • 6.3 Online Pharmacies
  • 6.4 Retail Pharmacies
  • 6.5 Other Distribution Channels

7 Global Endocrinology Drugs Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Transdermal
  • 7.4 Injectable

8 Global Endocrinology Drugs Market, By End User

  • 8.1 Introduction
  • 8.2 Ambulatory Surgical Centers
  • 8.3 Hospitals
  • 8.4 Other End Users

9 Global Endocrinology Drugs Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott Laboratories,
  • 11.2 Eli Lilly And Company
  • 11.3 F. Hoffmann La Roche Ltd.
  • 11.4 Novartis International AG
  • 11.5 Pfizer Inc.
  • 11.6 Alacer Corporation
  • 11.7 Novo Nordisk A/S
  • 11.8 Facet Biotech Corporation
  • 11.9 Sanofi
  • 11.10 Takeda Pharmaceutical Company Limited
  • 11.11 Merck KGaA
  • 11.12 AstraZeneca Plc
  • 11.13 Lee Pharmaceuticals
  • 11.14 MannKind
  • 11.15 Acerus Pharmaceuticals Corp
  • 11.16 Bayer AG
  • 11.17 Endo International Plc
  • 11.18 Beta Cell NV
  • 11.19 Hanmi Pharm Co. Ltd
  • 11.20 Ipsen Pharma

List of Tables

  • Table 1 Global Endocrinology Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Endocrinology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
  • Table 3 Global Endocrinology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
  • Table 4 Global Endocrinology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
  • Table 5 Global Endocrinology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
  • Table 6 Global Endocrinology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
  • Table 7 Global Endocrinology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
  • Table 8 Global Endocrinology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
  • Table 9 Global Endocrinology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
  • Table 10 Global Endocrinology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
  • Table 11 Global Endocrinology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 12 Global Endocrinology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 13 Global Endocrinology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 14 Global Endocrinology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 15 Global Endocrinology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 16 Global Endocrinology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 17 Global Endocrinology Drugs Market Outlook, By Oral (2021-2030) ($MN)
  • Table 18 Global Endocrinology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 19 Global Endocrinology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 20 Global Endocrinology Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 21 Global Endocrinology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 22 Global Endocrinology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 23 Global Endocrinology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 24 North America Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 25 North America Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
  • Table 26 North America Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
  • Table 27 North America Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
  • Table 28 North America Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
  • Table 29 North America Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
  • Table 30 North America Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
  • Table 31 North America Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
  • Table 32 North America Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
  • Table 33 North America Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
  • Table 34 North America Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 35 North America Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 36 North America Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 37 North America Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 38 North America Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 39 North America Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 40 North America Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
  • Table 41 North America Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 42 North America Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 43 North America Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 44 North America Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 45 North America Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 46 North America Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 47 Europe Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 48 Europe Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
  • Table 49 Europe Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
  • Table 50 Europe Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
  • Table 51 Europe Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
  • Table 52 Europe Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
  • Table 53 Europe Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
  • Table 54 Europe Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
  • Table 55 Europe Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
  • Table 56 Europe Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
  • Table 57 Europe Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 58 Europe Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 59 Europe Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 60 Europe Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 61 Europe Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 62 Europe Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 63 Europe Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
  • Table 64 Europe Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 65 Europe Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 66 Europe Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 67 Europe Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 68 Europe Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 69 Europe Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 70 Asia Pacific Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 71 Asia Pacific Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
  • Table 72 Asia Pacific Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
  • Table 73 Asia Pacific Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
  • Table 74 Asia Pacific Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
  • Table 75 Asia Pacific Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
  • Table 76 Asia Pacific Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
  • Table 77 Asia Pacific Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
  • Table 78 Asia Pacific Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
  • Table 79 Asia Pacific Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
  • Table 80 Asia Pacific Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 81 Asia Pacific Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 82 Asia Pacific Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 83 Asia Pacific Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 84 Asia Pacific Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 85 Asia Pacific Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 86 Asia Pacific Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
  • Table 87 Asia Pacific Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 88 Asia Pacific Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 89 Asia Pacific Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 90 Asia Pacific Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 91 Asia Pacific Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 92 Asia Pacific Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 93 South America Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 94 South America Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
  • Table 95 South America Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
  • Table 96 South America Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
  • Table 97 South America Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
  • Table 98 South America Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
  • Table 99 South America Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
  • Table 100 South America Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
  • Table 101 South America Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
  • Table 102 South America Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
  • Table 103 South America Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 104 South America Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 105 South America Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 106 South America Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 107 South America Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 108 South America Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 109 South America Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
  • Table 110 South America Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 111 South America Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 112 South America Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 113 South America Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 114 South America Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 115 South America Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 116 Middle East & Africa Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 117 Middle East & Africa Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
  • Table 118 Middle East & Africa Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
  • Table 119 Middle East & Africa Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
  • Table 120 Middle East & Africa Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
  • Table 121 Middle East & Africa Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
  • Table 122 Middle East & Africa Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
  • Table 123 Middle East & Africa Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
  • Table 124 Middle East & Africa Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
  • Table 125 Middle East & Africa Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
  • Table 126 Middle East & Africa Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 127 Middle East & Africa Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 128 Middle East & Africa Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 129 Middle East & Africa Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 130 Middle East & Africa Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 131 Middle East & Africa Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 132 Middle East & Africa Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
  • Table 133 Middle East & Africa Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 134 Middle East & Africa Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 135 Middle East & Africa Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 136 Middle East & Africa Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 137 Middle East & Africa Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 138 Middle East & Africa Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)